Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
142 shown of 8,968 total abstracts
  1. Abstract 93932026-04-03 · 14:15 CT · Hall B1
    FLAURA-4: Tagrisso (osimertinib) 2L in NSCLC
    F. Andre, S. Peters · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  2. Abstract 97362026-04-03 · 14:30 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    P. Schmid, S. Antonia, H. Rugo · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  3. Abstract 98312026-04-03 · 21:30 CT · E450
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-221 study)
    N. Rizvi, H. Borghaei, S. Tolaney · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  4. Abstract 92972026-04-01 · 14:00 CT · E450
    Long-term follow-up of Opdivo 2L for NSCLC: CheckMate-742
    L. Paz-Ares, S. Peters, S. Tolaney · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  5. Abstract 95122026-04-02 · 14:30 CT · S406
    FLAURA-742: Tagrisso (osimertinib) 1L in NSCLC
    N. Rizvi, C. Robert · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  6. Abstract 95812026-04-02 · 15:00 CT · Hall B1
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-326
    S. Tolaney, C. Saura · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  7. Abstract 93172026-04-03 · 20:45 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-706 study)
    P. Schmid, C. Saura, S. Tolaney, et al. · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  8. Abstract 98112026-04-03 · 21:30 CT · S100A
    Long-term follow-up of Imfinzi 3L+ for SCLC: PACIFIC-468
    F. Andre, M. Krop · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  9. Abstract 96792026-04-02 · 19:15 CT · E450
    FLAURA-791: Tagrisso (osimertinib) neoadjuvant in NSCLC
    J. Cortes, G. Curigliano · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract 94392026-04-01 · 20:15 CT · Arie Crown Theater
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    S. Antonia, M.C. Garassino, P. Schmid · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  11. Abstract 97292026-04-01 · 14:00 CT · E450
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    S. Antonia, F. Andre, T. Mok, et al. · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  12. Abstract 92332026-04-01 · 20:15 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-15 study)
    E. Winer, S. Tolaney, T. Mok, et al. · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  13. Abstract 96822026-04-01 · 19:30 CT · Hall B1
    Long-term follow-up of Imfinzi adjuvant for SCLC: PACIFIC-951
    J. Cortes, S. Tolaney, S. Antonia, et al. · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  14. Abstract 92142026-04-02 · 14:45 CT · S100A
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-749 study)
    M. Krop, L. Paz-Ares, P. Schmid · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  15. Abstract 92652026-04-02 · 14:30 CT · Hall B1
    FLAURA-491: Tagrisso (osimertinib) maintenance in NSCLC
    M. Reck, N. Rizvi, S. Peters, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  16. Abstract 90932026-04-03 · 14:00 CT · Arie Crown Theater
    FLAURA-769: Tagrisso (osimertinib) 1L in NSCLC
    S. Tolaney, J. Brahmer, S. Peters · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  17. Abstract 92192026-04-05 · 15:45 CT · Hall B1
    Quality of life outcomes with Tagrisso in patients with NSCLC
    M. Reck, M.C. Garassino, F. Andre · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  18. Abstract 99282026-04-05 · 19:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-355 study)
    C. Saura, H. Borghaei, T. Mok · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  19. Abstract 93772026-04-02 · 21:15 CT · Arie Crown Theater
    Quality of life outcomes with Tecentriq in patients with NSCLC
    C. Saura, N. Rizvi, E. Winer, et al. · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  20. Abstract 92422026-04-05 · 14:30 CT · Hall B1
    Quality of life outcomes with Opdivo in patients with NSCLC
    S. Tolaney, C. Robert, N. Rizvi · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  21. Abstract 98922026-04-03 · 13:00 CT · E450
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-35
    R. Herbst, H. Rugo, J. Brahmer, et al. · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  22. Abstract 94892026-04-04 · 20:30 CT · S100A
    PACIFIC-89: Imfinzi (durvalumab) adjuvant in NSCLC
    J. Brahmer, H. Rugo, S. Modi, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  23. Abstract 94582026-04-05 · 20:00 CT · S406
    Long-term follow-up of Enhertu neoadjuvant for NSCLC: DESTINY-Breast-683
    E. Winer, M.C. Garassino · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  24. Abstract 91412026-04-04 · 19:30 CT · S406
    Long-term follow-up of Opdivo neoadjuvant for NSCLC: CheckMate-286
    S. Antonia, E. Winer · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  25. Abstract 93102026-04-01 · 16:15 CT · S406
    PACIFIC-387: Imfinzi (durvalumab) 2L in SCLC
    J. Brahmer, M. Krop · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  26. Abstract 97812026-04-02 · 13:00 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-514
    E. Winer, C. Robert, S. Tolaney, et al. · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  27. Abstract 96792026-04-01 · 20:30 CT · S100A
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-844
    L. Paz-Ares, M. Reck · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  28. Abstract 92172026-04-01 · 14:30 CT · Hall B1
    PACIFIC-996: Imfinzi (durvalumab) 1L in SCLC
    S. Antonia, C. Robert, F. Andre, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  29. Abstract 95272026-04-04 · 19:45 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-101 study)
    S. Tolaney, E. Winer · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  30. Abstract 92472026-04-02 · 14:30 CT · E450
    Long-term follow-up of Opdivo 1L for NSCLC: CheckMate-126
    C. Saura, S. Peters, S. Antonia, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  31. Abstract 91212026-04-02 · 16:45 CT · E450
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    L. Paz-Ares, F. Andre, M.C. Garassino, et al. · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  32. Abstract 93042026-04-04 · 20:15 CT · S406
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-248
    S. Tolaney, S. Peters, P. Schmid, et al. · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  33. Abstract 97582026-04-04 · 19:30 CT · Hall B1
    Quality of life outcomes with Imfinzi in patients with NSCLC
    F. Andre, J. Brahmer, S. Tolaney, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  34. Abstract 97952026-04-02 · 15:30 CT · S406
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-350
    S. Modi, L. Paz-Ares, P. Schmid · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  35. Abstract 91322026-04-05 · 20:45 CT · S406
    DESTINY-Breast-303: Enhertu (trastuzumab deruxtecan) 2L in NSCLC
    M. Krop, H. Rugo, T. Mok, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  36. Abstract 91852026-04-03 · 14:30 CT · E450
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    G. Curigliano, S. Peters, M. Reck, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  37. Abstract 93572026-04-04 · 16:30 CT · S100A
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-908
    M.C. Garassino, H. Borghaei · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  38. Abstract 92982026-04-05 · 20:30 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-339 study)
    H. Borghaei, G. Curigliano, R. Herbst, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  39. Abstract 92152026-04-01 · 18:15 CT · E450
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-583 study)
    L. Paz-Ares, J. Brahmer, M. Krop · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  40. Abstract 93622026-04-01 · 13:45 CT · E450
    Long-term follow-up of Imfinzi adjuvant for NSCLC: PACIFIC-930
    C. Saura, A. Spira, C. Robert · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  41. Abstract 97062026-04-05 · 19:15 CT · S406
    IMpower-203: Tecentriq (atezolizumab) 1L in NSCLC
    G. Curigliano, S. Antonia · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  42. Abstract 90512026-04-05 · 18:15 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-493
    M. Reck, P. Schmid, R. Herbst · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  43. Abstract 92712026-04-02 · 15:45 CT · S100A
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-648
    S. Peters, F. Andre, J. Brahmer · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  44. Abstract 96512026-04-03 · 16:30 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-855
    C. Saura, S. Tolaney, S. Peters, et al. · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  45. Abstract 91152026-04-01 · 15:30 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi neoadjuvant for SCLC: PACIFIC-179
    J. Cortes, S. Modi, S. Tolaney · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  46. Abstract 96032026-04-04 · 15:00 CT · S100A
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-187 study)
    L. Paz-Ares, R. Herbst, J. Brahmer, et al. · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  47. Abstract 92342026-04-02 · 15:00 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-599
    N. Rizvi, E. Winer, C. Saura, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  48. Abstract 95432026-04-04 · 19:00 CT · E450
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-304
    M. Krop, S. Peters, E. Winer, et al. · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  49. Abstract 95112026-04-01 · 13:30 CT · E450
    FLAURA-243: Tagrisso (osimertinib) adjuvant in NSCLC
    R. Herbst, N. Rizvi, S. Modi, et al. · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  50. Abstract 96442026-04-03 · 21:30 CT · S406
    FLAURA-751: Tagrisso (osimertinib) 1L in NSCLC
    T. Mok, M. Krop, A. Spira · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  51. Abstract 95242026-04-02 · 16:30 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-271
    L. Paz-Ares, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  52. Abstract 97842026-04-01 · 13:45 CT · S100A
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-787 study)
    S. Tolaney, R. Herbst · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  53. Abstract 93262026-04-04 · 21:00 CT · S100A
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-466 study)
    E. Winer, J. Cortes, P. Schmid, et al. · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  54. Abstract 90202026-04-03 · 19:15 CT · Hall B1
    FLAURA-773: Tagrisso (osimertinib) 1L in NSCLC
    R. Herbst, P. Schmid, L. Paz-Ares, et al. · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  55. Abstract 99032026-04-02 · 18:45 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-254 study)
    S. Tolaney, M. Krop, C. Robert, et al. · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  56. Abstract 91312026-04-03 · 15:45 CT · Hall B1
    Quality of life outcomes with Imfinzi in patients with SCLC
    S. Antonia, J. Cortes · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  57. Abstract 94292026-04-01 · 21:30 CT · E450
    Long-term follow-up of Imfinzi 1L for NSCLC: PACIFIC-271
    S. Modi, M.C. Garassino, M. Krop, et al. · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  58. Abstract 94422026-04-01 · 16:00 CT · S406
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-598 study)
    L. Paz-Ares, C. Saura, H. Borghaei · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  59. Abstract 97672026-04-01 · 15:15 CT · S406
    Long-term follow-up of Opdivo 1L for NSCLC: CheckMate-659
    H. Borghaei, S. Peters, T. Mok, et al. · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  60. Abstract 97722026-04-01 · 16:15 CT · E450
    Long-term follow-up of Imfinzi 2L for NSCLC: PACIFIC-330
    G. Curigliano, J. Cortes, T. Mok · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  61. Abstract 90702026-04-03 · 13:45 CT · S100A
    Long-term follow-up of Enhertu 3L+ for NSCLC: DESTINY-Breast-422
    C. Saura, M.C. Garassino · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  62. Abstract 91362026-04-05 · 20:00 CT · S100A
    Long-term follow-up of Keytruda neoadjuvant for SCLC: KEYNOTE-528
    S. Tolaney, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  63. Abstract 96532026-04-04 · 20:30 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-290 study)
    A. Spira, T. Mok, S. Modi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  64. Abstract 95302026-04-01 · 20:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda neoadjuvant for NSCLC: KEYNOTE-119
    J. Cortes, M. Reck, J. Brahmer · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  65. Abstract 99372026-04-03 · 13:00 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in SCLC
    F. Andre, M. Krop, M.C. Garassino, et al. · Karolinska Institute
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  66. Abstract 92932026-04-04 · 14:15 CT · S406
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-989 study)
    J. Cortes, C. Robert · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  67. Abstract 93832026-04-01 · 14:00 CT · E450
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-321
    M. Reck, E. Winer, S. Modi, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  68. Abstract 92862026-04-02 · 16:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-990 study)
    M.C. Garassino, G. Curigliano, R. Herbst · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  69. Abstract 98182026-04-01 · 18:15 CT · S406
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-793
    J. Cortes, S. Modi, S. Peters, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  70. Abstract 90352026-04-03 · 13:30 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-534
    N. Rizvi, T. Mok, M. Krop, et al. · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  71. Abstract 90692026-04-05 · 15:00 CT · E450
    FLAURA-66: Tagrisso (osimertinib) adjuvant in NSCLC
    M. Reck, S. Peters, H. Borghaei · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  72. Abstract 91402026-04-04 · 19:15 CT · S100A
    Long-term follow-up of Tecentriq 3L+ for NSCLC: IMpower-892
    M. Reck, M.C. Garassino · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  73. Abstract 91762026-04-04 · 13:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-664 study)
    M. Reck, T. Mok, M.C. Garassino · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  74. Abstract 95862026-04-05 · 14:30 CT · S100A
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-830
    A. Spira, M. Krop, J. Cortes · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  75. Abstract 91622026-04-05 · 21:30 CT · S406
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-112 study)
    A. Spira, C. Saura, J. Cortes, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  76. Abstract 98492026-04-04 · 18:45 CT · Arie Crown Theater
    IMpower-463: Tecentriq (atezolizumab) adjuvant in NSCLC
    C. Robert, H. Rugo · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  77. Abstract 96872026-04-02 · 16:15 CT · Hall B1
    FLAURA-898: Tagrisso (osimertinib) neoadjuvant in NSCLC
    N. Rizvi, A. Spira, P. Schmid, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  78. Abstract 93542026-04-04 · 21:45 CT · E450
    CheckMate-373: Opdivo (nivolumab) 1L in NSCLC
    J. Cortes, S. Modi · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  79. Abstract 90282026-04-05 · 19:15 CT · Hall B1
    FLAURA-570: Tagrisso (osimertinib) maintenance in NSCLC
    E. Winer, A. Spira, H. Borghaei, et al. · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  80. Abstract 92582026-04-01 · 14:00 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-114 study)
    S. Tolaney, R. Herbst, H. Borghaei, et al. · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  81. Abstract 92422026-04-03 · 13:00 CT · S100A
    Long-term follow-up of Opdivo adjuvant for NSCLC: CheckMate-973
    L. Paz-Ares, J. Brahmer, H. Borghaei, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  82. Abstract 93262026-04-02 · 18:15 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-977
    M.C. Garassino, N. Rizvi · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  83. Abstract 93642026-04-01 · 15:45 CT · Hall B1
    Long-term follow-up of Tecentriq maintenance for NSCLC: IMpower-138
    M.C. Garassino, L. Paz-Ares, J. Cortes, et al. · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  84. Abstract 92262026-04-04 · 14:30 CT · S406
    FLAURA-25: Tagrisso (osimertinib) adjuvant in NSCLC
    F. Andre, N. Rizvi, T. Mok, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  85. Abstract 97912026-04-03 · 16:45 CT · S100A
    KEYNOTE-888: Keytruda (pembrolizumab) adjuvant in NSCLC
    H. Borghaei, T. Mok · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  86. Abstract 92432026-04-05 · 14:15 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-145
    S. Tolaney, S. Antonia, P. Schmid · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  87. Abstract 97882026-04-03 · 20:45 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-994
    E. Winer, L. Paz-Ares, N. Rizvi, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  88. Abstract 99662026-04-01 · 20:00 CT · S406
    Long-term follow-up of Opdivo 2L for NSCLC: CheckMate-174
    M. Krop, T. Mok, H. Borghaei, et al. · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  89. Abstract 90442026-04-03 · 21:00 CT · Arie Crown Theater
    FLAURA-579: Tagrisso (osimertinib) maintenance in NSCLC
    C. Saura, S. Modi, A. Spira, et al. · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  90. Abstract 90472026-04-01 · 18:00 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-313
    L. Paz-Ares, C. Robert, J. Brahmer, et al. · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  91. Abstract 98742026-04-01 · 20:30 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-645 study)
    C. Saura, T. Mok, N. Rizvi, et al. · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  92. Abstract 94692026-04-05 · 15:00 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-300 study)
    R. Herbst, M.C. Garassino, S. Peters, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  93. Abstract 97212026-04-04 · 20:00 CT · Hall B1
    IMpower-332: Tecentriq (atezolizumab) adjuvant in NSCLC
    P. Schmid, R. Herbst · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  94. Abstract 99582026-04-03 · 14:45 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with SCLC
    P. Schmid, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  95. Abstract 99422026-04-04 · 14:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-935 study)
    M.C. Garassino, A. Spira · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  96. Abstract 95142026-04-05 · 14:15 CT · S100A
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-396
    H. Rugo, S. Antonia · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  97. Abstract 91902026-04-05 · 19:45 CT · Hall B1
    Long-term follow-up of Imfinzi maintenance for SCLC: PACIFIC-48
    M.C. Garassino, C. Saura, P. Schmid · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  98. Abstract 91452026-04-03 · 21:15 CT · E450
    DESTINY-Breast-627: Enhertu (trastuzumab deruxtecan) maintenance in NSCLC
    S. Modi, H. Rugo · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  99. Abstract 97552026-04-04 · 14:00 CT · E450
    Quality of life outcomes with Enhertu in patients with NSCLC
    H. Borghaei, N. Rizvi · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  100. Abstract 96842026-04-04 · 14:15 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-172
    S. Modi, S. Tolaney, L. Paz-Ares · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  101. Abstract 92532026-04-01 · 13:30 CT · Arie Crown Theater
    FLAURA-609: Tagrisso (osimertinib) 1L in NSCLC
    C. Robert, M. Reck, A. Spira, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  102. Abstract 93732026-04-03 · 16:00 CT · Hall B1
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    H. Rugo, F. Andre, S. Peters, et al. · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  103. Abstract 94662026-04-01 · 15:00 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-751
    J. Brahmer, P. Schmid, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  104. Abstract 91002026-04-05 · 14:30 CT · S100A
    DESTINY-Breast-917: Enhertu (trastuzumab deruxtecan) 1L in NSCLC
    S. Peters, J. Brahmer, L. Paz-Ares · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  105. Abstract 94072026-04-05 · 18:45 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-167 study)
    S. Peters, E. Winer, T. Mok, et al. · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  106. Abstract 96392026-04-04 · 19:45 CT · E450
    DESTINY-Breast-702: Enhertu (trastuzumab deruxtecan) 1L in NSCLC
    C. Robert, M. Krop, N. Rizvi · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  107. Abstract 95582026-04-01 · 21:30 CT · S100A
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-296 study)
    A. Spira, C. Saura · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  108. Abstract 96332026-04-02 · 18:15 CT · S100A
    FLAURA-957: Tagrisso (osimertinib) 3L+ in NSCLC
    P. Schmid, A. Spira · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  109. Abstract 96792026-04-04 · 18:45 CT · Arie Crown Theater
    KEYNOTE-334: Keytruda (pembrolizumab) maintenance in NSCLC
    H. Borghaei, C. Robert, T. Mok · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  110. Abstract 97292026-04-03 · 21:15 CT · Arie Crown Theater
    Long-term follow-up of Enhertu adjuvant for NSCLC: DESTINY-Breast-153
    H. Borghaei, J. Cortes, M. Krop · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  111. Abstract 91992026-04-04 · 14:15 CT · Arie Crown Theater
    DESTINY-Breast-11: Enhertu (trastuzumab deruxtecan) 1L in NSCLC
    M.C. Garassino, N. Rizvi, T. Mok, et al. · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  112. Abstract 90372026-04-03 · 19:15 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-65 study)
    J. Cortes, S. Tolaney, M.C. Garassino, et al. · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  113. Abstract 94092026-04-04 · 16:45 CT · E450
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-737
    E. Winer, T. Mok, H. Borghaei · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  114. Abstract 94622026-04-04 · 18:45 CT · Arie Crown Theater
    PACIFIC-465: Imfinzi (durvalumab) 2L in SCLC
    G. Curigliano, S. Antonia, M. Krop, et al. · Mayo Clinic
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  115. Abstract 91682026-04-05 · 20:30 CT · S100A
    PACIFIC-708: Imfinzi (durvalumab) 2L in SCLC
    H. Borghaei, S. Tolaney, C. Robert, et al. · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  116. Abstract 96122026-04-05 · 16:00 CT · S100A
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-902 study)
    P. Schmid, C. Saura · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  117. Abstract 91582026-04-03 · 20:45 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-674
    A. Spira, S. Peters, P. Schmid, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  118. Abstract 92782026-04-05 · 15:30 CT · E450
    DESTINY-Breast-525: Enhertu (trastuzumab deruxtecan) 3L+ in NSCLC
    A. Spira, M. Reck · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  119. Abstract 99952026-04-02 · 13:15 CT · S100A
    Long-term follow-up of Tecentriq 2L for NSCLC: IMpower-537
    S. Antonia, R. Herbst, G. Curigliano, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  120. Abstract 94772026-04-02 · 21:30 CT · Arie Crown Theater
    Long-term follow-up of Keytruda adjuvant for NSCLC: KEYNOTE-485
    P. Schmid, C. Robert · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  121. Abstract 98742026-04-04 · 13:15 CT · S406
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-115
    F. Andre, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  122. Abstract 96722026-04-04 · 15:30 CT · S406
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-898 study)
    H. Rugo, G. Curigliano, R. Herbst, et al. · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  123. Abstract 93602026-04-05 · 14:00 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with NSCLC
    A. Spira, J. Cortes, P. Schmid, et al. · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  124. Abstract 99642026-04-03 · 15:45 CT · E450
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-338 study)
    T. Mok, M. Reck, L. Paz-Ares · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  125. Abstract 97562026-04-01 · 13:30 CT · S406
    FLAURA-919: Tagrisso (osimertinib) neoadjuvant in NSCLC
    P. Schmid, H. Rugo, N. Rizvi, et al. · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  126. Abstract 94942026-04-01 · 16:45 CT · S100A
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-813
    M. Krop, S. Peters, A. Spira, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  127. Abstract 91022026-04-02 · 21:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-622 study)
    N. Rizvi, R. Herbst, S. Modi · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  128. Abstract 97482026-04-05 · 19:30 CT · S406
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-37
    C. Robert, L. Paz-Ares, J. Cortes, et al. · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  129. Abstract 95292026-04-04 · 20:00 CT · S406
    FLAURA-103: Tagrisso (osimertinib) 1L in NSCLC
    S. Modi, L. Paz-Ares, G. Curigliano, et al. · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  130. Abstract 90032026-04-03 · 20:45 CT · S406
    PACIFIC-897: Imfinzi (durvalumab) neoadjuvant in SCLC
    H. Rugo, S. Tolaney, S. Modi, et al. · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  131. Abstract 94952026-04-02 · 21:30 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-284 study)
    P. Schmid, C. Saura, C. Robert, et al. · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  132. Abstract 94732026-04-04 · 18:30 CT · E450
    PACIFIC-738: Imfinzi (durvalumab) 3L+ in SCLC
    T. Mok, C. Robert · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  133. Abstract 95262026-04-04 · 18:30 CT · E450
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-798
    S. Tolaney, C. Robert, S. Antonia · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  134. Abstract 94592026-04-03 · 19:45 CT · Hall B1
    FLAURA-744: Tagrisso (osimertinib) 2L in NSCLC
    J. Cortes, H. Borghaei, N. Rizvi · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  135. Abstract 90472026-04-02 · 19:30 CT · E450
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-381 study)
    C. Robert, S. Modi, T. Mok, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  136. Abstract 91882026-04-04 · 20:00 CT · E450
    Long-term follow-up of Imfinzi 2L for NSCLC: PACIFIC-830
    J. Brahmer, R. Herbst, E. Winer · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  137. Abstract 92232026-04-03 · 13:15 CT · S100A
    IMpower-514: Tecentriq (atezolizumab) 3L+ in NSCLC
    S. Modi, M. Krop, J. Brahmer, et al. · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  138. Abstract 98502026-04-01 · 19:00 CT · Arie Crown Theater
    Long-term follow-up of Keytruda adjuvant for NSCLC: KEYNOTE-134
    T. Mok, M. Reck · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  139. Abstract 91932026-04-01 · 16:15 CT · S100A
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-764
    M. Krop, M. Reck, M.C. Garassino · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  140. Abstract 95592026-04-02 · 13:15 CT · E450
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-545
    H. Borghaei, J. Cortes, E. Winer, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  141. Abstract 92492026-04-03 · 15:15 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-487
    J. Brahmer, R. Herbst, C. Robert, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  142. Abstract 95822026-04-02 · 14:30 CT · E450
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-409 study)
    J. Brahmer, M.C. Garassino · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.